The purpose of the study is to see if this step‑by‑step approach can improve outcomes for people with this high‑risk lymphoma. Participants will receive the initial combination of glofitamab plus chemotherapy in several treatment cycles, then undergo infusion of a CAR‑T product such as Breyanzi or Yescarta, and finally receive further glofitamab doses as consolidation. The whole sequence takes place over several months, with regular clinic visits for infusions, monitoring, and safety checks.

Throughout the trial, doctors will watch for any side effects, assess how well the disease responds, and evaluate overall health and quality of life. Follow‑up continues after the last treatment to see how long the response lasts and to track any late‑appearing effects.

The medications will be given in different ways – some as tablets taken by mouth and others through an intravenous infusion (given directly into a vein) or subcutaneous injection (given under the skin). The study will be conducted in two parts. The first part will determine the right dose of the drug combinations, while the second part will further study how well these doses work and what side effects they may cause.

Throughout the study, doctors will monitor patients’ health, check how well the treatment is working, and track any side effects. They will look at how many patients respond to treatment and how long the response lasts. For some patients, they will also measure the amount of cancer cells remaining in the blood or bone marrow after treatment.

Participants in the study will receive one of two different treatment paths. One group will receive glofitamab along with gemcitabine and oxaliplatin. The other group will receive rituximab combined with gemcitabine and oxaliplatin. These medications are administered through an IV infusion, which is a method where medicine is delivered directly into a vein using a needle or a small tube.

During the course of the study, the health and response to the treatments will be monitored. The study will track how long patients live and how long they live without the disease getting worse. Researchers will also look for side effects, such as cytokine-release syndrome, which is a temporary reaction where the body’s immune system becomes overly active. The study involves regular check-ups to observe how the medications affect the body and the cancer.

The purpose of the study is to understand how this combination of medications affects a condition known as Cytokine Release Syndrome (CRS), which can occur when the immune system reacts strongly to certain treatments. The study will monitor how often CRS happens and how severe it is when patients receive the treatment. Patients will receive the medications through an intravenous (IV) infusion, which means the drugs are given directly into the bloodstream through a vein. The study will also look at how well patients tolerate the treatment and any side effects they might experience.

Participants in the study will receive the treatment over a period of time, with regular check-ups to monitor their health and the effects of the treatment. The study aims to provide valuable information on the safety and effectiveness of this treatment combination for patients with relapsed or refractory DLBCL. The trial is expected to continue for several years, allowing researchers to gather comprehensive data on the treatment’s impact on patients’ health and quality of life.

The purpose of the study is to learn how well AZD0486 works and how safe it is for patients with this type of cancer. Participants in the study will receive the treatment through an intravenous infusion, which means the medicine will be given directly into a vein. The study will follow participants over time to see how their cancer responds to the treatment and to monitor any side effects they might experience.

Throughout the study, researchers will collect information on how the treatment affects the cancer and the overall health of the participants. This includes looking at changes in the size of the cancer, any improvements in symptoms, and any side effects that occur. The study aims to provide valuable information that could lead to new treatment options for people with Non-Hodgkin Lymphoma.

The purpose of the study is to compare how well patients respond to the treatment with and without Selinexor. The study is divided into two phases. In the first phase, the focus is on how many patients show a positive response to the treatment. In the second phase, the study looks at how long patients live without the disease getting worse. Some patients will receive a placebo, which is a tablet that looks like the real medication but does not contain the active drug, to compare the effects of the actual treatment.

Participants in the study will receive the treatment over a period of time, and their health will be monitored to see how the disease responds. The study aims to provide more information on whether adding Selinexor to the existing treatment can improve outcomes for patients with RR DLBCL. This research could help in developing better treatment strategies for this type of lymphoma in the future.

Participants in the study will receive Epcoritamab along with other medications, which may include Revlimid (containing lenalidomide), Decortin (containing prednisolone), Cyclophosphamide, Truxima (containing rituximab), IMBRUVICA (containing ibrutinib), Venetoclax (also known as ABT-199), Adriblastin (containing doxorubicin hydrochloride), Polivy (containing polatuzumab vedotin), and Golcadomide (also known as BMS-986369/CC-99282). Some participants may receive a placebo instead of one of these medications. The study will help determine the best dose of Epcoritamab to use in future research.

The study will take place over several years, with participants receiving treatment and being monitored for any side effects or changes in their condition. The researchers will look at how the cancer responds to the treatment, how long any positive effects last, and how long it takes for the cancer to progress or for participants to need another type of treatment. This information will help doctors understand how effective Epcoritamab is when used with other cancer treatments for people with B-cell Non-Hodgkin’s lymphoma.

The purpose of the study is to determine if adding Polatuzumab vedotin to the R-ICE regimen improves the time patients remain free from cancer events, which is referred to as event-free survival. Participants in the study will receive the treatment through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein. The study will follow participants over a period to monitor their response to the treatment and any side effects they may experience.

Throughout the study, researchers will collect information on various outcomes, such as how long patients remain free from cancer progression, the overall response to the treatment, and any side effects. The study will also look at the quality of life of participants during and after treatment. This research is important for understanding whether the addition of Polatuzumab vedotin can provide better outcomes for patients with relapsed or refractory DLBCL compared to the standard R-ICE treatment alone.

The purpose of the study is to evaluate the safety and effectiveness of the combination treatment compared to the standard treatment without Polatuzumab Vedotin. The study will monitor how well patients respond to the treatment and how long they live after receiving it. It will also look at any side effects, with a particular focus on a condition called peripheral neuropathy, which involves nerve damage that can cause weakness, numbness, and pain, usually in the hands and feet.

Participants in the study will receive their treatments through intravenous infusions, which means the medication is delivered directly into a vein. The study will take place over a period of time, with regular check-ups to monitor the patients’ health and response to the treatment. The trial aims to provide valuable information that could lead to better treatment options for patients with relapsed or refractory DLBCL.

The purpose of the study is to evaluate how these medications work together in treating patients with DLBCL. Participants in the study will receive either the combination of Brentuximab Vedotin, Lenalidomide, and Rituximab or a combination that includes a placebo instead of Brentuximab Vedotin. A placebo is a substance with no active medication. The study will compare the effects of these treatments over a period of time to see which is more effective in preventing the cancer from getting worse.

Throughout the study, participants will receive the medications through subcutaneous injections, which means the medication is given under the skin, and oral capsules, which are taken by mouth. The study will monitor the participants’ health and the progression of their cancer to gather information on the effectiveness and safety of the treatment combinations. The goal is to find out if the combination of these medications can help improve the outcomes for patients with relapsed or refractory DLBCL.

The medications being tested are both types of targeted therapies. Mosunetuzumab is a specially designed antibody that helps the immune system recognize and attack cancer cells. Polatuzumab vedotin is a medication that combines an antibody with a substance that kills cancer cells. The study will test these medications given together through intravenous infusion or as an injection under the skin.

The study will check if this combination of medications is safe to use and how well it works in treating the lymphoma. Researchers will monitor patients for side effects and measure if the cancer responds to the treatment. The study will also look at how long any improvements last and how the medications move through the body. Additional medications may be given to help manage side effects, including prednisone, dexamethasone, paracetamol, and other supportive care medicines.

Participants in the study will receive the treatments through an intravenous infusion, which means the medication is given directly into the bloodstream. The study will monitor how the body responds to the treatment over a period of time, looking at factors such as how well the cancer responds and any side effects that may occur. The study will also explore how the treatment affects the immune system and how long the modified cells remain active in the body.

This trial is an important step in understanding how these new therapies can help people with Large B-Cell Lymphoma who have limited treatment options. By participating, researchers hope to gather valuable information that could lead to new and effective treatments for this type of cancer in the future.

The medications involved in this study include Vincristine Sulfate, Cyclophosphamide, Doxorubicin Hydrochloride, Prednisone, and Rituximab. These are commonly used in chemotherapy, which is a type of cancer treatment that uses drugs to destroy cancer cells. The study will involve administering these medications through different methods such as intravenous infusion, which means delivering the medication directly into a vein, and subcutaneous injection, which involves injecting the medication under the skin.

Participants in the study will receive one of the treatment options over a period of time, and their health will be monitored to see how well the treatment works. The study will look at various outcomes, such as how long patients live without the disease getting worse, the duration of response to the treatment, and the overall survival rate. The study will also assess the safety of the treatments and their impact on the quality of life of the participants. The trial is expected to continue until the end of 2025.

The purpose of the study is to see how effective the combination of these medications is in helping the body accept the CAR T cell therapy and to compare it to the use of Fludarabine and Cyclophosphamide alone. Participants in the study will receive either the combination of Fludarabine, Cyclophosphamide, and ALLO-647 or just Fludarabine and Cyclophosphamide before receiving the ALLO-501A therapy. The study will monitor how well the cancer responds to the treatment and how long the response lasts. It will also look at the safety of the treatment and any side effects that may occur.

The study will take place over a period of time, with participants receiving treatment and being monitored for their response to the therapy. The goal is to gather information that could help improve treatment options for people with relapsed or refractory Large B-Cell Lymphoma. This research could potentially lead to new ways to treat this type of cancer more effectively in the future.